Jasper Therapeutics JSPR
NASDAQ JSPR
$0.70 +0.01 (+2.02%)
At close: Sep 10, 2026 · 4:00 PM EDT

Jasper Therapeutics (JSPR) Total Debt (2022)

Jasper Therapeutics (JSPR) posted Total Debt of $18000.0 for Q4 2022.

Analysis

Jasper Therapeutics (JSPR) Total Debt (2022) Analysis & Trends

Jasper Therapeutics has reported Total Debt for 1 years, with the latest figure at $18000.0 in Q4 2022.

  • On a quarterly basis, Total Debt changed N/A year-over-year to $18000.0 in Q4 2022; TTM through Dec 2022 was $18000.0, a N/A change from a year earlier, with the FY2022 full-year figure at $18000.0, changed N/A from the prior year.
  • Total Debt was $18000.0 for Q4 2022 at Jasper Therapeutics.
  • The five-year high for Total Debt was $18000.0 in Q4 2022, with the low at $18000.0 in Q4 2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn 62.75 Bn
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn 28.66 Bn
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn -
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn 1.99 Bn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn -
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn 591.00 Mn
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn -
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn 8.09 Bn
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn -
10 Jasper Therapeutics 20.11 Mn 20.11 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2022 18,000.00